Aktis Oncology
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
17 Drydock Ave Ste 17-401, Boston, Massa...Website
www.aktisoncology.comRevenue
$10.1 MillionStock Symbol
AKTSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Aktis Oncology
Aktis Oncology is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on pioneering targeted alpha radiopharmaceuticals for cancer treatment. The company has developed a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting particles to solid tumors, including breast, lung, colorectal, bladder, and liver cancers, that have historically been difficult to treat with radiopharmaceuticals. Its pipeline includes candidates such as AKY-2519, aimed at expanding breakthrough cancer therapies to broader patient populations with significant unmet medical needs.Explore more
Aktis Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aktis Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Aktis Oncology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Aktis Oncology
Check if Aktis Oncology has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Aktis Oncology has new funding data
Check out if Aktis Oncology is spiking on competitors!
Click to see if Aktis Oncology had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Aktis Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Aktis Oncology launches new products
Recommended Actions
Reach out to Masked Content who joined Aktis Oncology as Masked Content
Find 2 more new buyers
Compare Similar Companies to Aktis Oncology
Compare insights from companies similar to Aktis Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aktis Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aktis Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aktis Oncology.
Aktis Oncology financials insights
Gather financial insights about Aktis Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$161M
2024
Series B
$175M
Aktis Oncology Tech Stack
A closer look at the technologies used by Aktis Oncology
See more technologies
Most Recent Scoops
Person-Based
Clinical Operations
Open Position
Project
Aktis Oncology has reported clinical imaging data for AKY-1189, its nectin-4 targeted radioconjugate, demonstrating robust tumor uptake with rapid clearance from normal tissues, and dosimetry data showing absorbed doses in the kidney and bone marrow not exceeding those observed with FDA-approved products PLUVICTO and LUTATHERA. Tumor uptake measured by SUVmax across five different tumor types ranged from high single digits to approximately 100, with a central tendency in the 20s to 40s.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Aktis Oncology has initiated the Actinium-2 Phase I-B dose escalation study for AKY-1189, enrolling patients post-PADCEV in bladder cancer as well as nectin-4 uptake-positive patients across other tumor types including triple-negative breast, HR-positive breast, and lung cancers, with dose escalation starting at 4 megabecquerels and escalating up to 12 megabecquerels, and data expected to be presented in Q1 2027.
Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Partnership, Pharmaceuticals
Aktis Oncology News & Media
Aktis Oncology to Present at Upcoming September Investor Conferences
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September.Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the second quarter ended June 30, 2026.Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the Jefferies Global Healthcare Conference in New York, New York. The presentation will t
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aktis Oncology
Sign Up For FreeTo access detailed company insights
Aktis Oncology is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, focused on pioneering targeted alpha radiopharmaceuticals for cancer treatment. The company has developed a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting particles to solid tumors, including breast, lung, colorectal,... Read More
